Low-Ogestrel Shortage: What Providers and Prescribers Need to Know in 2026

Patients presenting to your practice struggling to fill Low-Ogestrel 28 Day is a common and manageable situation in 2026. While there is no active FDA-declared national shortage of norgestrel/ethinyl estradiol, localized pharmacy stockouts continue to create frustration for patients and unnecessary calls to clinician offices. This guide provides clinically actionable information on the current supply environment, substitution options, and patient management strategies.

Current Availability Status (2026)

As of 2026, the FDA's Drug Shortages Database does not list norgestrel/ethinyl estradiol (Low-Ogestrel) as a shortage medication. The drug is manufactured by Dr. Reddy's Laboratories and is part of a competitive generic market that includes Cryselle (Teva), Elinest, and Turqoz.

Patient reports of difficulty finding Low-Ogestrel most commonly reflect individual pharmacy inventory decisions rather than upstream supply issues. Chains frequently maintain only one preferred norgestrel/EE generic on their formulary; if it isn't Low-Ogestrel, patients may be told the medication is unavailable when, in fact, a bioequivalent is stocked.

Bioequivalent Substitutions: Clinical Considerations

The following generics are FDA-rated as bioequivalent to Low-Ogestrel and contain identical active ingredient profiles (norgestrel 0.3 mg / ethinyl estradiol 0.03 mg):

Cryselle 28 (Teva) — Widely distributed, typically well-stocked at national chains

Elinest (28 Day) — Identical formulation; manufactured separately

Turqoz (28 Day) — Newer branded generic; growing pharmacy availability

For mid-cycle substitution within the same bioequivalent class, backup contraception is generally not required if the patient has been taking active pills consistently and is switching without a gap. Standard prescribing guidance applies for new starts or any gap in pill-taking.

When Bioequivalents Are Not Available: Alternative COC Considerations

If identical generics are also unavailable, clinical judgment should guide selection of an alternative COC. Key factors to consider include estrogen dose tolerance, progestin androgenicity preferences, and any comorbidities. Comparable monophasic COC options include:

Levora / Portia (levonorgestrel 0.15 mg / EE 0.03 mg) — Same estrogen dose (30 mcg); levonorgestrel is closely structurally related to norgestrel (levonorgestrel is the biologically active enantiomer of norgestrel). Minimal adjustment expected.

Sprintec (norgestimate 0.25 mg / EE 0.035 mg) — Slightly higher estrogen (35 mcg); norgestimate is less androgenic than norgestrel. Suitable if patient had androgenic side effects on Low-Ogestrel.

Yaz / Gianvi (drospirenone 3 mg / EE 0.02 mg) — Lower estrogen dose, anti-androgenic progestin; appropriate for patients with acne or PMDD; potassium monitoring note for patients on ACE inhibitors, ARBs, NSAIDs, or potassium-sparing diuretics.

Prescribing Practice Tip: Write Brand-Agnostic Prescriptions

Rather than specifying "Low-Ogestrel" by brand name, prescribe by generic name: "norgestrel 0.3 mg / ethinyl estradiol 0.03 mg tablet, 28-day pack" and allow generic substitution. This gives the dispensing pharmacist flexibility to fill with whichever bioequivalent is in stock — Cryselle, Elinest, Turqoz, or Low-Ogestrel — without requiring a callback or new prescription.

If your patient specifically tolerates one formulation better (e.g., due to inactive ingredient allergies), then brand-specific prescribing is appropriate. Be aware that lactose intolerance may be relevant, as some formulations contain lactose as an inactive ingredient.

Patient Counseling Recommendations

When patients call reporting Low-Ogestrel is out of stock, provide the following guidance:

Ask the pharmacy if they have Cryselle, Elinest, or Turqoz — these are the same medication.

If unable to find at the current pharmacy, try a different chain or independent pharmacy.

Use backup contraception if there has been any gap in pill-taking while searching.

Consider transitioning to mail-order pharmacy for a 90-day supply to reduce the frequency of this issue going forward.

A Tool to Help Your Patients Find Low-Ogestrel

medfinder for Providers is a service designed to support clinicians whose patients are having difficulty locating medications. medfinder contacts pharmacies in the patient's area and identifies which ones can fill the prescription, reducing calls to your office and helping patients access their medication faster.

See our related guide: How to Help Your Patients Find Low-Ogestrel In Stock — A Provider's Guide.